Clinical Trial Update: Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the efficacy and safety of PI3K inhibitors in relapsed/refractory large granular lymphocytic leukemia has completed, reporting early si…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Large Granular Lymphocytic Leukemia

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Relapsed/Refractory Large Granular T Lymphocytic Leukemia | Phase 1 | Status: COMPLETED